Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in ...

Novo Nordisk to invest $1.2 billion in Denmark for a new production site ... impacting Novo Nordisk’s 2024 profit and 2025 share buyback plans. On Monday, Danish pharmaceutical firm Novo ...

The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing ... A slight negative effect on operating profit growth and a reduction in free ...

The 40,000-square-metre (430,000-square-feet) production facility and warehouse in Odense “marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new ...

The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production ... A slight negative effect on operating profit growth and a reduction ...

Novo Nordisk plans to invest $1.2 billion in a new production site for rare-disease medicines in Denmark. The Danish ... negative impact on 2025 operating profit growth and the company isn't ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and ...